The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Autologous Matrix-induced Chondrogenesis-Global Market Insights and Sales Trends 2025
Synopsis
Autologous matrix-induced chondrogenesis (AMIC) is a surgical technique used to repair cartilage defects in the knee joint.
The global Autologous Matrix-induced Chondrogenesis market size is expected to reach US$ 149.5 million by 2029, growing at a CAGR of 4.9% from 2023 to 2029. The market is mainly driven by the significant applications of Autologous Matrix-induced Chondrogenesis in various end use industries. The expanding demands from the Knees Joint and Other, are propelling Autologous Matrix-induced Chondrogenesis market. Hyaluronic Acid, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Collagen segment is estimated at % CAGR for the next seven-year period.
The market for AMIC is driven by the growing prevalence of knee injuries and osteoarthritis, leading to a demand for advanced and minimally invasive cartilage repair techniques. The increasing focus on sports and physical activities further fuels the adoption of AMIC procedures.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Autologous Matrix-induced Chondrogenesis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Autologous Matrix-induced Chondrogenesis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Autologous Matrix-induced Chondrogenesis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Autologous Matrix-induced Chondrogenesis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Autologous Matrix-induced Chondrogenesis covered in this report include JRI Orthopaedics Ltd, BioTissue, Anika Therapeutics, B. Braun Melsungen, Arthro-Kinetics, Geistlich Pharma, CartiHeal, Matricel and Smith & Nephew, etc.
The global Autologous Matrix-induced Chondrogenesis market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
JRI Orthopaedics Ltd
BioTissue
Anika Therapeutics
B. Braun Melsungen
Arthro-Kinetics
Geistlich Pharma
CartiHeal
Matricel
Smith & Nephew
Zimmer Biomet Holdings
Global Autologous Matrix-induced Chondrogenesis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Autologous Matrix-induced Chondrogenesis market, Segment by Type:
Hyaluronic Acid
Collagen
Polyethylene Glycol (PEG)
Poly Lactic-Co-Glycolic Acid (PGLA)
Global Autologous Matrix-induced Chondrogenesis market, by Application
Knees Joint
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Autologous Matrix-induced Chondrogenesis companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Autologous matrix-induced chondrogenesis (AMIC) is a surgical technique used to repair cartilage defects in the knee joint.
The global Autologous Matrix-induced Chondrogenesis market size is expected to reach US$ 149.5 million by 2029, growing at a CAGR of 4.9% from 2023 to 2029. The market is mainly driven by the significant applications of Autologous Matrix-induced Chondrogenesis in various end use industries. The expanding demands from the Knees Joint and Other, are propelling Autologous Matrix-induced Chondrogenesis market. Hyaluronic Acid, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Collagen segment is estimated at % CAGR for the next seven-year period.
The market for AMIC is driven by the growing prevalence of knee injuries and osteoarthritis, leading to a demand for advanced and minimally invasive cartilage repair techniques. The increasing focus on sports and physical activities further fuels the adoption of AMIC procedures.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Autologous Matrix-induced Chondrogenesis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Autologous Matrix-induced Chondrogenesis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Autologous Matrix-induced Chondrogenesis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Autologous Matrix-induced Chondrogenesis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Autologous Matrix-induced Chondrogenesis covered in this report include JRI Orthopaedics Ltd, BioTissue, Anika Therapeutics, B. Braun Melsungen, Arthro-Kinetics, Geistlich Pharma, CartiHeal, Matricel and Smith & Nephew, etc.
The global Autologous Matrix-induced Chondrogenesis market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
JRI Orthopaedics Ltd
BioTissue
Anika Therapeutics
B. Braun Melsungen
Arthro-Kinetics
Geistlich Pharma
CartiHeal
Matricel
Smith & Nephew
Zimmer Biomet Holdings
Global Autologous Matrix-induced Chondrogenesis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Autologous Matrix-induced Chondrogenesis market, Segment by Type:
Hyaluronic Acid
Collagen
Polyethylene Glycol (PEG)
Poly Lactic-Co-Glycolic Acid (PGLA)
Global Autologous Matrix-induced Chondrogenesis market, by Application
Knees Joint
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Autologous Matrix-induced Chondrogenesis companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Autologous Matrix-induced Chondrogenesis
1.1 Autologous Matrix-induced Chondrogenesis Market Overview
1.1.1 Autologous Matrix-induced Chondrogenesis Product Scope
1.1.2 Autologous Matrix-induced Chondrogenesis Market Status and Outlook
1.2 Global Autologous Matrix-induced Chondrogenesis Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Autologous Matrix-induced Chondrogenesis Market Size by Region (2018-2029)
1.4 Global Autologous Matrix-induced Chondrogenesis Historic Market Size by Region (2018-2023)
1.5 Global Autologous Matrix-induced Chondrogenesis Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Autologous Matrix-induced Chondrogenesis Market Size (2018-2029)
1.6.1 North America Autologous Matrix-induced Chondrogenesis Market Size (2018-2029)
1.6.2 Europe Autologous Matrix-induced Chondrogenesis Market Size (2018-2029)
1.6.3 Asia-Pacific Autologous Matrix-induced Chondrogenesis Market Size (2018-2029)
1.6.4 Latin America Autologous Matrix-induced Chondrogenesis Market Size (2018-2029)
1.6.5 Middle East & Africa Autologous Matrix-induced Chondrogenesis Market Size (2018-2029)
2 Autologous Matrix-induced Chondrogenesis Market by Type
2.1 Introduction
2.1.1 Hyaluronic Acid
2.1.2 Collagen
2.1.3 Polyethylene Glycol (PEG)
2.1.4 Poly Lactic-Co-Glycolic Acid (PGLA)
2.2 Global Autologous Matrix-induced Chondrogenesis Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Autologous Matrix-induced Chondrogenesis Historic Market Size by Type (2018-2023)
2.2.2 Global Autologous Matrix-induced Chondrogenesis Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Autologous Matrix-induced Chondrogenesis Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Autologous Matrix-induced Chondrogenesis Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Autologous Matrix-induced Chondrogenesis Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Autologous Matrix-induced Chondrogenesis Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Autologous Matrix-induced Chondrogenesis Revenue Breakdown by Type (2018-2029)
3 Autologous Matrix-induced Chondrogenesis Market Overview by Application
3.1 Introduction
3.1.1 Knees Joint
3.1.2 Other
3.2 Global Autologous Matrix-induced Chondrogenesis Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Autologous Matrix-induced Chondrogenesis Historic Market Size by Application (2018-2023)
3.2.2 Global Autologous Matrix-induced Chondrogenesis Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Autologous Matrix-induced Chondrogenesis Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Autologous Matrix-induced Chondrogenesis Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Autologous Matrix-induced Chondrogenesis Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Autologous Matrix-induced Chondrogenesis Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Autologous Matrix-induced Chondrogenesis Revenue Breakdown by Application (2018-2029)
4 Autologous Matrix-induced Chondrogenesis Competition Analysis by Players
4.1 Global Autologous Matrix-induced Chondrogenesis Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Autologous Matrix-induced Chondrogenesis as of 2022)
4.3 Date of Key Players Enter into Autologous Matrix-induced Chondrogenesis Market
4.4 Global Top Players Autologous Matrix-induced Chondrogenesis Headquarters and Area Served
4.5 Key Players Autologous Matrix-induced Chondrogenesis Product Solution and Service
4.6 Competitive Status
4.6.1 Autologous Matrix-induced Chondrogenesis Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 JRI Orthopaedics Ltd
5.1.1 JRI Orthopaedics Ltd Profile
5.1.2 JRI Orthopaedics Ltd Main Business
5.1.3 JRI Orthopaedics Ltd Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
5.1.4 JRI Orthopaedics Ltd Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2018-2023)
5.1.5 JRI Orthopaedics Ltd Recent Developments
5.2 BioTissue
5.2.1 BioTissue Profile
5.2.2 BioTissue Main Business
5.2.3 BioTissue Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
5.2.4 BioTissue Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2018-2023)
5.2.5 BioTissue Recent Developments
5.3 Anika Therapeutics
5.3.1 Anika Therapeutics Profile
5.3.2 Anika Therapeutics Main Business
5.3.3 Anika Therapeutics Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
5.3.4 Anika Therapeutics Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2018-2023)
5.3.5 B. Braun Melsungen Recent Developments
5.4 B. Braun Melsungen
5.4.1 B. Braun Melsungen Profile
5.4.2 B. Braun Melsungen Main Business
5.4.3 B. Braun Melsungen Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
5.4.4 B. Braun Melsungen Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2018-2023)
5.4.5 B. Braun Melsungen Recent Developments
5.5 Arthro-Kinetics
5.5.1 Arthro-Kinetics Profile
5.5.2 Arthro-Kinetics Main Business
5.5.3 Arthro-Kinetics Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
5.5.4 Arthro-Kinetics Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2018-2023)
5.5.5 Arthro-Kinetics Recent Developments
5.6 Geistlich Pharma
5.6.1 Geistlich Pharma Profile
5.6.2 Geistlich Pharma Main Business
5.6.3 Geistlich Pharma Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
5.6.4 Geistlich Pharma Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2018-2023)
5.6.5 Geistlich Pharma Recent Developments
5.7 CartiHeal
5.7.1 CartiHeal Profile
5.7.2 CartiHeal Main Business
5.7.3 CartiHeal Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
5.7.4 CartiHeal Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2018-2023)
5.7.5 CartiHeal Recent Developments
5.8 Matricel
5.8.1 Matricel Profile
5.8.2 Matricel Main Business
5.8.3 Matricel Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
5.8.4 Matricel Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2018-2023)
5.8.5 Matricel Recent Developments
5.9 Smith & Nephew
5.9.1 Smith & Nephew Profile
5.9.2 Smith & Nephew Main Business
5.9.3 Smith & Nephew Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
5.9.4 Smith & Nephew Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2018-2023)
5.9.5 Smith & Nephew Recent Developments
5.10 Zimmer Biomet Holdings
5.10.1 Zimmer Biomet Holdings Profile
5.10.2 Zimmer Biomet Holdings Main Business
5.10.3 Zimmer Biomet Holdings Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
5.10.4 Zimmer Biomet Holdings Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2018-2023)
5.10.5 Zimmer Biomet Holdings Recent Developments
6 North America
6.1 North America Autologous Matrix-induced Chondrogenesis Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Autologous Matrix-induced Chondrogenesis Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Autologous Matrix-induced Chondrogenesis Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Autologous Matrix-induced Chondrogenesis Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Autologous Matrix-induced Chondrogenesis Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Autologous Matrix-induced Chondrogenesis Market Dynamics
11.1 Autologous Matrix-induced Chondrogenesis Industry Trends
11.2 Autologous Matrix-induced Chondrogenesis Market Drivers
11.3 Autologous Matrix-induced Chondrogenesis Market Challenges
11.4 Autologous Matrix-induced Chondrogenesis Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
